MCID: THY028
MIFTS: 72

Thyroid Cancer

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Thyroid Cancer

MalaCards integrated aliases for Thyroid Cancer:

Name: Thyroid Cancer 12 77 38 30 56 44 15
Thyroid Carcinoma 12 30 56 6 15 17 74
Thyroid Neoplasm 12 17 74
Neoplasm of the Thyroid Gland 30 6
Thyroid Neoplasms 56 45
Malignant Neoplasm of Thyroid Gland 12
Malignant Tumour of Thyroid Gland 12
Head and Neck Cancer, Thyroid 12
Malignant Neoplasm of Thyroid 74
Neoplasm of Thyroid Gland 12
Thyroid Gland Carcinoma 12
Thyroid Gland Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1781 DOID:3963
KEGG 38 H00032
ICD9CM 36 193
MeSH 45 D013964
SNOMED-CT 69 94098005
ICD10 34 C73

Summaries for Thyroid Cancer

MedlinePlus : 44 Your thyroid is a butterfly-shaped gland in your neck, just above your collarbone. It makes hormones that help the body work normally. There are several types of cancer of the thyroid gland. You are at greater risk if you Are between ages 25 and 65 Are a woman Are Asian Have a family member who has had thyroid disease Have had radiation treatments to your head or neck You should see a doctor if you have a lump or swelling in your neck. Doctors use a physical exam, thyroid tests, other blood and imaging tests, and a biopsy to diagnose thyroid cancer. Treatment depends on the type of cancer you have and how far the cancer has spread. Many patients receive a combination of treatments. They may include surgery, radioactive iodine, hormone treatment, radiation therapy, chemotherapy, or targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

MalaCards based summary : Thyroid Cancer, also known as thyroid carcinoma, is related to thyroid cancer, nonmedullary, 2 and thyroid cancer, nonmedullary, 1, and has symptoms including tinnitus, snoring and sore throat. An important gene associated with Thyroid Cancer is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Thyroid cancer and Transcriptional misregulation in cancer. The drugs Cometriq and Lenvima have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and testes, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A thyroid cancer that has material basis in epithelial cells.

Wikipedia : 77 Thyroid cancer is cancer that develops from the tissues of the thyroid gland. It is a disease in which... more...

Related Diseases for Thyroid Cancer

Diseases related to Thyroid Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 639)
# Related Disease Score Top Affiliating Genes
1 thyroid cancer, nonmedullary, 2 35.0 BRAF HRAS NRAS PIK3CA RET
2 thyroid cancer, nonmedullary, 1 34.1 BRAF GAS5 H19 HOTAIR MALAT1 PTCSC3
3 thyroid carcinoma, familial medullary 34.0 KRAS MALAT1 RET
4 differentiated thyroid carcinoma 31.2 BRAF HRAS KRAS NRAS RET
5 melanoma, cutaneous malignant 1 31.0 BRAF HRAS NRAS PIK3CA
6 malignant struma ovarii 30.9 HRAS NRAS RET
7 ovarian germ cell teratoma 30.8 NRAS RET
8 adrenocortical carcinoma, hereditary 30.6 BRAF H19 NRAS PIK3CA
9 sarcoma 30.6 BRAF HOTAIR HRAS KRAS PIK3CA
10 ovary adenocarcinoma 30.5 HRAS KRAS PIK3CA
11 pituitary adenoma 30.5 H19 HOTAIR MALAT1
12 adenocarcinoma 30.5 AKT1 BRAF H19 HRAS KRAS MALAT1
13 benign struma ovarii 30.5 HRAS NRAS RET
14 leukemia, chronic lymphocytic 2 30.5 BRAF HRAS KRAS NRAS
15 leukemia, chronic lymphocytic 30.5 BRAF HRAS KRAS NRAS
16 neurofibromatosis, type iv, of riccardi 30.5 CDKN2B-AS1 HRAS RET
17 ovarian serous cystadenocarcinoma 30.5 AKT1 BRAF HRAS NRAS PIK3CA
18 erdheim-chester disease 30.4 BRAF NRAS PIK3CA
19 giant congenital nevus 30.4 HRAS NRAS
20 endocrine gland cancer 30.4 AKT1 HRAS KRAS RET
21 adenoid cystic carcinoma 30.4 AKT1 HRAS KRAS PIK3CA
22 brain cancer 30.4 AKT1 BRAF HRAS NRAS PIK3CA
23 gastrointestinal stromal tumor 30.2 AKT1 BRAF HOTAIR KRAS
24 tongue squamous cell carcinoma 30.1 AFAP1-AS1 AKT1 MALAT1 UCA1
25 squamous cell carcinoma, head and neck 30.1 AKT1 BRAF GAS5 H19 HOTAIR HRAS
26 leukemia, chronic myeloid 30.1 H19 HOTAIR HRAS NRAS UCA1
27 laryngeal squamous cell carcinoma 30.1 CDKN2B-AS1 H19 HOTAIR MALAT1
28 melanoma 30.1 BRAF CDKN2B-AS1 GAS5 H19 HOTAIR MALAT1
29 glioblastoma 30.0 AKT1 BRAF GAS5 H19 HOTAIR HRAS
30 cholangiocarcinoma 30.0 AFAP1-AS1 AKT1 BRAF H19 KRAS MALAT1
31 squamous cell carcinoma 30.0 AKT1 BRAF CDKN2B-AS1 H19 HOTAIR HRAS
32 leukemia, acute myeloid 29.9 AKT1 CDKN2B-AS1 HOTAIR HRAS KRAS MALAT1
33 medulloblastoma 29.9 AKT1 CDKN2B-AS1 H19 HOTAIR NRAS PIK3CA
34 small cell cancer of the lung 29.9 AKT1 HOTAIR MALAT1 PIK3CA
35 breast cancer 29.8 AKT1 BRAF CASC2 CDKN2B-AS1 GAS5 H19
36 kidney cancer 29.6 GAS5 H19 HOTAIR MALAT1 PVT1
37 colorectal cancer 29.5 AFAP1-AS1 AKT1 BRAF CASC2 CDKN2B-AS1 GAS5
38 myeloma, multiple 29.5 AKT1 BRAF GAS5 H19 HOTAIR HRAS
39 endometrial cancer 29.3 AKT1 BRAF CASC2 GAS5 H19 HOTAIR
40 esophageal cancer 29.3 AKT1 CASC2 CDKN2B-AS1 GAS5 H19 HOTAIR
41 lung cancer susceptibility 3 29.2 AFAP1-AS1 AKT1 BRAF CASC2 GAS5 H19
42 renal cell carcinoma, nonpapillary 29.2 CASC2 GAS5 H19 HOTAIR MALAT1 PVT1
43 ovarian cancer 29.1 AFAP1-AS1 AKT1 BRAF CDKN2B-AS1 GAS5 H19
44 nasopharyngeal carcinoma 29.1 AFAP1-AS1 AKT1 CDKN2B-AS1 GAS5 H19 HOTAIR
45 lung cancer 29.0 AFAP1-AS1 AKT1 BRAF CASC2 CDKN2B-AS1 GAS5
46 glioma 28.9 BRAF CASC2 CDKN2B-AS1 GAS5 H19 HOTAIR
47 gastric cancer 28.8 AFAP1-AS1 AKT1 CASC2 CDKN2B-AS1 GAS5 H19
48 hepatocellular carcinoma 28.6 AFAP1-AS1 AKT1 CASC2 CDKN2B-AS1 FALEC GAS5
49 prostate cancer 28.5 AKT1 CASC2 CDKN2B-AS1 FALEC GAS5 H19
50 thyroid cancer, nonmedullary, 5 12.6

Comorbidity relations with Thyroid Cancer via Phenotypic Disease Network (PDN):


Hypertension, Essential Hypothyroidism
Lymphomatous Thyroiditis Postsurgical Hypothyroidism

Graphical network of the top 20 diseases related to Thyroid Cancer:



Diseases related to Thyroid Cancer

Symptoms & Phenotypes for Thyroid Cancer

UMLS symptoms related to Thyroid Cancer:


tinnitus, snoring, sore throat, coughing, vertigo/dizziness, equilibration disorder

GenomeRNAi Phenotypes related to Thyroid Cancer according to GeneCards Suite gene sharing:

27 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.56 HRAS KRAS PIK3CA BRAF
2 Decreased viability GR00106-A-0 10.56 KRAS
3 Decreased viability GR00221-A-1 10.56 AKT1 HRAS KRAS PIK3CA RET NRAS
4 Decreased viability GR00221-A-2 10.56 AKT1 HRAS KRAS PIK3CA RET
5 Decreased viability GR00221-A-3 10.56 AKT1 HRAS NRAS
6 Decreased viability GR00221-A-4 10.56 AKT1 PIK3CA RET BRAF
7 Decreased viability GR00231-A 10.56 RET
8 Decreased viability GR00301-A 10.56 KRAS RET BRAF
9 Decreased viability GR00381-A-1 10.56 KRAS BRAF
10 Decreased viability GR00402-S-2 10.56 AKT1 HRAS KRAS PIK3CA RET BRAF
11 Decreased cell migration GR00055-A-1 9.55 AKT1 BRAF HRAS KRAS PIK3CA
12 Increased cell migration GR00055-A-3 8.92 BRAF HRAS KRAS PIK3CA

MGI Mouse Phenotypes related to Thyroid Cancer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 AKT1 BRAF HRAS KRAS NRAS PIK3CA

Drugs & Therapeutics for Thyroid Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Cometriq 19 50 CABOZANTINIB S-MALATE Exelixis November 2012
2
Lenvima 19 50 LENVATINIB MESYLATE Eisai February 2015
3
Nexavar 19 50 SORAFENIB TOSYLATE Bayer/Onyx December 2005
4
Sensipar 19 CINACALCET HYDROCHLORIDE Amgen March 2004
5
Vandetanib 19 50 vandetanib AstraZeneca April 2011

Drugs for Thyroid Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 425)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7553-56-2 807
2
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
3
Glucagon Approved Phase 4,Phase 3,Not Applicable 16941-32-5
4
Parathyroid hormone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9002-64-6
5
Lenvatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 417716-92-8
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
7
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
8
Sodium Citrate Approved, Investigational Phase 4,Phase 2,Phase 1 68-04-2
9
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 1 439-14-5 3016
10
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
11
Acetaminophen Approved Phase 4 103-90-2 1983
12
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
13
Codeine Approved, Illicit Phase 4 76-57-3 5284371
14
Tyrosine Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 1 60-18-4 6057
15
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 77-92-9 311
16 cadexomer iodine Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Nutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Anti-Infective Agents, Local Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1,Not Applicable
23 glucocorticoids Phase 4,Phase 1,Phase 2
24 Betamethasone Valerate Phase 4 2152-44-5
25 Respiratory System Agents Phase 4,Phase 3
26 Betamethasone-17,21-dipropionate Phase 4
27 Betamethasone sodium phosphate Phase 4
28 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
29 Betamethasone benzoate Phase 4
30 Betamethasone acetate Phase 4
31 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
33 Anti-Asthmatic Agents Phase 4,Phase 3
34 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
36 Anesthetics Phase 4,Phase 3,Phase 1,Not Applicable
37 Incretins Phase 4,Phase 3,Not Applicable
38 Glucagon-Like Peptide 1 Phase 4,Phase 3,Not Applicable
39 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Narcotics Phase 4,Not Applicable
41 Analgesics Phase 4,Phase 2,Not Applicable
42 Anesthetics, General Phase 4,Phase 1,Not Applicable
43 Adjuvants, Anesthesia Phase 4,Phase 1
44 Analgesics, Opioid Phase 4,Not Applicable
45 Anesthetics, Intravenous Phase 4,Phase 1
46 Citrate Phase 4,Phase 2,Phase 1
47 rGLP-1 protein Phase 4,Phase 3
48 Analgesics, Non-Narcotic Phase 4,Phase 2,Not Applicable
49 Antipyretics Phase 4
50 Antitussive Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 656)
# Name Status NCT ID Phase Drugs
1 Radiolabeled Molecules for Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
2 rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors Unknown status NCT00902122 Phase 4 rAd-p53 gene;p53 gene therapy
3 Total Thyroidectomy With Harmonic Scalpel® Unknown status NCT00385983 Phase 4
4 Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy Unknown status NCT02652884 Phase 4 phosphate and betamethasone acetate, 2 mL.;saline 0.9% NaCl
5 Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer Completed NCT00604318 Phase 4 rhTSH
6 Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal. Completed NCT00001730 Phase 4 Thyrogen
7 Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia Completed NCT01308320 Phase 4 fentanyl citrate;saline
8 Is the Routine Pressure Dressing After Thyroidectomy Necessary? Completed NCT00400465 Phase 4
9 Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus Completed NCT02465515 Phase 4
10 Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results Completed NCT00858104 Phase 4
11 A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer Recruiting NCT03573960 Phase 4 Lenvatinib
12 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
13 Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy Recruiting NCT02946918 Phase 4 Levothyroxine
14 Minimizing Narcotic Analgesics After Endocrine Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
15 To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer Active, not recruiting NCT01496313 Phase 4 300mg vandetanib;150mg vandetanib
16 Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients Unknown status NCT00435851 Phase 3 Thyrogen, thyroid hormone withdrawal, iode 131
17 Medico-economic Evaluation Comparing the Use of Ultrasonic Scissors to the Conventional Techniques of Haemostasis in Thyroid Surgery by Cervicotomy Unknown status NCT01551914 Phase 3
18 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
19 Laser Therapy of Benign Thyroid Nodules Unknown status NCT00150150 Phase 3
20 Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer Completed NCT01843062 Phase 3 Selumetinib;Placebo;Radioactive Iodine Therapy
21 Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer Completed NCT01083550 Phase 2, Phase 3
22 A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
23 The Usefulness of Staining Lymph Nodes During Operations for Cancer Thyroid in Detecting the Nodes That Have Cancer Completed NCT00794053 Phase 3
24 Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Completed NCT00984282 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
25 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) Completed NCT01321554 Phase 3 Lenvatinib;Placebo;Lenvatinib
26 Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) Completed NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
27 Multicenter Study Differentiated Thyroid Carcinoma Completed NCT00144079 Phase 3
28 Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC Completed NCT01137097 Phase 2, Phase 3
29 Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients Completed NCT01616316 Phase 2, Phase 3
30 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Completed NCT00795782 Phase 3
31 Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration Completed NCT00196729 Phase 3 Thyrogen + Radioiodine (131I)
32 Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy Completed NCT02112370 Phase 3 Ropivacaine with epinephrine injection
33 Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain Completed NCT01126060 Phase 3 Usage of Fibrin sealant
34 Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer Completed NCT00123760 Phase 2, Phase 3
35 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
36 A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes Completed NCT02152371 Phase 3 Dulaglutide;Placebo;Insulin Glargine;Metformin
37 Percutaneous Radiofrequency Thermal Ablation in Compressive Thyroid Nodules Completed NCT01649206 Phase 3
38 Elastography Interest in the Management of Thyroid Nodules Completed NCT01335828 Phase 2, Phase 3
39 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
40 A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy Recruiting NCT03690388 Phase 3 Cabozantinib;Placebo
41 Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer Recruiting NCT03048877 Phase 3 Apatinib Oral Tablet;Placebo Oral Tablet
42 Donafenib in 131I-Refractory Differentiated Thyroid Cancer Recruiting NCT03602495 Phase 3 Donafenib;Placebo
43 Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? Recruiting NCT01837745 Phase 3 rhTSH stimulation;I131
44 Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Recruiting NCT01149161 Phase 2, Phase 3
45 Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology Recruiting NCT03498183 Phase 2, Phase 3 MIBI-Tc99m/Iodine-123
46 Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032) Active, not recruiting NCT02586337 Phase 2, Phase 3 Anlotinib;Placebo
47 Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer Active, not recruiting NCT01876784 Phase 3 Vandetanib (SAR390530);Placebo
48 Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer Active, not recruiting NCT00704730 Phase 3 XL184;Placebo
49 A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China Active, not recruiting NCT02966093 Phase 3 Lenvatinib;Placebo
50 Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer Active, not recruiting NCT02418247 Phase 2, Phase 3 I131;I123

Search NIH Clinical Center for Thyroid Cancer

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: thyroid neoplasms

Genetic Tests for Thyroid Cancer

Genetic tests related to Thyroid Cancer:

# Genetic test Affiliating Genes
1 Thyroid Cancer 30
2 Neoplasm of the Thyroid Gland 30
3 Thyroid Carcinoma 30

Anatomical Context for Thyroid Cancer

MalaCards organs/tissues related to Thyroid Cancer:

42
Thyroid, Lymph Node, Testes, Endothelial, Pituitary, Brain, Kidney

Publications for Thyroid Cancer

Articles related to Thyroid Cancer:

(show top 50) (show all 13445)
# Title Authors Year
1
Oncocytic poorly differentiated (insular) thyroid carcinoma mimicking metastatic adenocarcinoma. A case report and review of the literature. ( 30637975 )
2019
2
Pulmonary metastasis of mesonephric-like adenocarcinoma arising from the uterine body: a striking mimic of follicular thyroid carcinoma. ( 30471132 )
2019
3
Differences of HBME-1 Expression in Thyroid Follicular Adenoma and Follicular Thyroid Carcinoma by Ultrasound-Guided Fine-Needle Aspiration Biopsy. ( 30925956 )
2019
4
Spectroscopic identification of benign (follicular adenoma) and cancerous lesions (follicular thyroid carcinoma) in thyroid tissues. ( 30954022 )
2019
5
Incidental papillary thyroid cancer diagnosis in patient with adult-onset Still's disease-like manifestations. ( 30932443 )
2019
6
Nature of coexisting thyroid autoimmune disease determines success or failure of tumor immunity in thyroid cancer. ( 30616690 )
2019
7
Breast cancer prognosis is better in patients who develop subsequent metachronous thyroid cancer. ( 31042767 )
2019
8
131I uptake in tumoral calcinosis in a patient on hemodialysis treated for thyroid cancer. ( 30291041 )
2019
9
Aggressive papillary thyroid carcinoma in a child with type 2 congenital generalized lipodystrophy. ( 30864635 )
2019
10
Oncocytic and tall columnar type papillary thyroid carcinoma arising on a mature cystic teratoma: A case report and literature review. ( 30623925 )
2019
11
Coexistence of Papillary Thyroid Cancer and Hashimoto's Thyroiditis Developing within an Ovarian Mature Cystic Teratoma. ( 31001057 )
2019
12
Interobserver Variability in the Histopathologic Assessment of Extrathyroidal Extension of Well Differentiated Thyroid Carcinoma Supports the New American Joint Committee on Cancer Eighth Edition Criteria for Tumor Staging. ( 30913992 )
2019
13
Effects of tumor size on prognosis in differentiated thyroid carcinoma smaller than 2 cm. ( 30944617 )
2019
14
Risk of incident circulatory disease in patients treated for differentiated thyroid carcinoma with no history of cardiovascular disease. ( 30993728 )
2019
15
The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma. ( 31040741 )
2019
16
Naming difficulties after thyroid stimulating hormone suppression therapy in patients with differentiated thyroid carcinoma: a prospective cohort study. ( 31056722 )
2019
17
Body composition, resting energy expenditure and metabolic changes in women diagnosed with differentiated thyroid carcinoma. ( 31088334 )
2019
18
BRAF V600E Status and Stimulated Thyroglobulin at Ablation Time Increase Prognostic Value of American Thyroid Association Classification Systems for Persistent Disease in Differentiated Thyroid Carcinoma. ( 31093278 )
2019
19
Prognostic Impact of the Turin Criteria in Poorly Differentiated Thyroid Carcinoma. ( 31098668 )
2019
20
Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review. ( 31103041 )
2019
21
Pediatric differentiated thyroid carcinoma: The clinicopathological features and the coexistence of Hashimoto's thyroiditis. ( 29254871 )
2019
22
A Relook at the T Stage of Differentiated Thyroid Carcinoma with a Focus on Gross Extrathyroidal Extension. ( 30358515 )
2019
23
Determination of effective half-life of 131I in patients with differentiated thyroid carcinoma: comparison of cystatin C and creatinine-based estimation of renal function. ( 30382554 )
2019
24
The Use of Post-ablation Stimulated Thyroglobulin in Predicting Clinical Outcomes in Differentiated Thyroid Carcinoma - What Cut-off Values Should We Use? ( 30454940 )
2019
25
Oncologic outcomes in patients with 1-cm to 4-cm differentiated thyroid carcinoma according to extent of thyroidectomy. ( 30536465 )
2019
26
Conceptual interpretation of analysing and reporting of results on systematic review and meta-analysis of optimal extent of lateral neck dissection for well-differentiated thyroid carcinoma with metastatic lateral neck lymph nodes. ( 30612934 )
2019
27
LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA AND BONE METASTASES. ( 30657361 )
2019
28
Poorly differentiated thyroid carcinoma and poorly differentiated area in differentiated thyroid carcinoma: is there any difference? ( 30673845 )
2019
29
Brain Metastases From Differentiated Thyroid Carcinoma: Prevalence, Current Therapies, and Outcomes. ( 30706042 )
2019
30
Plasmacytoid morphology of poorly differentiated thyroid carcinoma: Diagnostic approach with a brief review of the literature. ( 30712289 )
2019
31
Free posterior tibial artery perforator flap for 2-stage tracheal reconstruction in patients after resection of well-differentiated thyroid carcinoma invading the trachea. ( 30729609 )
2019
32
Refining the tumor-node-metastasis staging system for individualized treatment of differentiated thyroid carcinoma. ( 30732964 )
2019
33
American Thyroid Association guidelines for the management of well-differentiated thyroid carcinoma. ( 30756497 )
2019
34
Re: Impact on Testicular Function of a Single Ablative Activity of 3.7 GBq Radioactive Iodine for Differentiated Thyroid Carcinoma. ( 30759647 )
2019
35
99mTc-Pertechnetate Scintigraphy Predicts Successful Postoperative Ablation in Differentiated Thyroid Carcinoma Patients Treated with Low Radioiodine Activities. ( 30784242 )
2019
36
Measuring thyroglobulin in patients with thyroglobulin autoantibodies: evaluation of the clinical impact of BRAHMS Kryptor® Tg-minirecovery test in a large series of patients with differentiated thyroid carcinoma. ( 30835250 )
2019
37
A rare invasion route for differentiated thyroid carcinoma: The tracheoesophageal common party wall. ( 30860597 )
2019
38
Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis. ( 30863162 )
2019
39
Impact of the updated TNM staging criteria on prediction of persistent disease in a differentiated thyroid carcinoma cohort. ( 30864625 )
2019
40
Significance of CEP78 and WDR62 gene expressions in differentiated thyroid carcinoma: Possible predictors of lateral lymph node metastasis. ( 30884127 )
2019
41
New molecular biomarkers in differentiated thyroid carcinoma: impact of miR-146, miR-221 and miR-222 levels in the evolution of the disease. ( 30887564 )
2019
42
Genomic Characterization of Differentiated Thyroid Carcinoma. ( 30912334 )
2019
43
Ectopic Papillary Thyroid Carcinoma Mimicking Esophageal Cancer in FDG PET: A Case Report. ( 30394932 )
2019
44
Prevalence of and risk factors for thyroid carcinoma in patients with familial adenomatous polyposis: results of a multicenter study in Japan and a systematic review. ( 30182306 )
2019
45
Barriers to thyroid cancer screening with ultrasound in patients with familial adenomatous polyposis. ( 30843614 )
2019
46
Toxic nodular goiter and thyroid cancer: Is hyperthyroidism protective against thyroid cancer? ( 31104806 )
2019
47
Papillary thyroid carcinoma in cervical lymph nodes with vanished thyroid gland after ablation of Graves' disease by radioactive iodine. ( 30854863 )
2019
48
The Impact of Hashimoto Thyroiditis on Thyroid Nodule Cytology and Risk of Thyroid Cancer. ( 30963137 )
2019
49
Distinct Clinical Manifestations of Thyroid Cancer After Hematopoietic Stem Cell Transplantation. ( 31102091 )
2019
50
BRAF gene mutations in synchronous papillary thyroid carcinoma and Langerhans cell histiocytosis co-existing in the thyroid gland: a case report and literature review. ( 30795755 )
2019

Variations for Thyroid Cancer

ClinVar genetic disease variations for Thyroid Cancer:

6 (show top 50) (show all 84)
# Gene Variation Type Significance SNP ID Assembly Location
1 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
2 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
3 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
4 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
5 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
6 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh38 Chromosome 12, 25245347: 25245347
7 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
8 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
9 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
10 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
11 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
12 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
13 KRAS NM_033360.3(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 GRCh37 Chromosome 12, 25398282: 25398282
14 KRAS NM_033360.3(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 GRCh38 Chromosome 12, 25245348: 25245348
15 HRAS NM_005343.2(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
16 HRAS NM_005343.2(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
17 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
18 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
19 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
20 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
21 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
22 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
23 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
24 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
25 RET NM_020975.5(RET): c.1900T> C (p.Cys634Arg) single nucleotide variant Pathogenic rs75076352 GRCh37 Chromosome 10, 43609948: 43609948
26 RET NM_020975.5(RET): c.1900T> C (p.Cys634Arg) single nucleotide variant Pathogenic rs75076352 GRCh38 Chromosome 10, 43114500: 43114500
27 RET NM_020975.4(RET): c.1902C> G (p.Cys634Trp) single nucleotide variant Pathogenic rs77709286 GRCh37 Chromosome 10, 43609950: 43609950
28 RET NM_020975.4(RET): c.1902C> G (p.Cys634Trp) single nucleotide variant Pathogenic rs77709286 GRCh38 Chromosome 10, 43114502: 43114502
29 RET NM_020975.4(RET): c.2753T> C (p.Met918Thr) single nucleotide variant Pathogenic rs74799832 GRCh37 Chromosome 10, 43617416: 43617416
30 RET NM_020975.4(RET): c.2753T> C (p.Met918Thr) single nucleotide variant Pathogenic rs74799832 GRCh38 Chromosome 10, 43121968: 43121968
31 BRAF NM_004333.5(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
32 BRAF NM_004333.5(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh38 Chromosome 7, 140753334: 140753334
33 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
34 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh38 Chromosome 14, 104780214: 104780214
35 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
36 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
37 BRAF NM_004333.4(BRAF): c.1802A> C (p.Lys601Thr) single nucleotide variant Pathogenic/Likely pathogenic rs397507484 GRCh37 Chromosome 7, 140453133: 140453133
38 BRAF NM_004333.4(BRAF): c.1802A> C (p.Lys601Thr) single nucleotide variant Pathogenic/Likely pathogenic rs397507484 GRCh38 Chromosome 7, 140753333: 140753333
39 KRAS NM_033360.3(KRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs121913240 GRCh37 Chromosome 12, 25380276: 25380276
40 KRAS NM_033360.3(KRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs121913240 GRCh38 Chromosome 12, 25227342: 25227342
41 KRAS NM_033360.3(KRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic rs121913240 GRCh37 Chromosome 12, 25380276: 25380276
42 KRAS NM_033360.3(KRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic rs121913240 GRCh38 Chromosome 12, 25227342: 25227342
43 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh37 Chromosome 12, 25380275: 25380275
44 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh38 Chromosome 12, 25227341: 25227341
45 KRAS NM_033360.3(KRAS): c.38G> T (p.Gly13Val) single nucleotide variant drug response rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
46 KRAS NM_033360.3(KRAS): c.38G> T (p.Gly13Val) single nucleotide variant drug response rs112445441 GRCh38 Chromosome 12, 25245347: 25245347
47 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh38 Chromosome 3, 179199690: 179199690
48 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh37 Chromosome 3, 178917478: 178917478
49 HRAS NM_176795.4(HRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Likely pathogenic rs121913233 GRCh38 Chromosome 11, 533874: 533874
50 HRAS NM_176795.4(HRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Likely pathogenic rs121913233 GRCh37 Chromosome 11, 533874: 533874

Copy number variations for Thyroid Cancer from CNVD:

7 (show all 22)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 48476 11 1 43400000 Gain Thyroid cancer
2 75266 13 18400000 72100000 Loss Thyroid cancer
3 80538 13 93800000 114142980 Loss Thyroid cancer
4 85051 14 37800000 43500000 Copy number FOXA1 Thyroid cancer
5 96631 15 90931472 91045475 Amplificationlicatio n IQGAP1 Thyroid cancer
6 111285 17 35400000 68400000 Gain Thyroid cancer
7 120295 18 23300000 71300000 Loss Thyroid cancer
8 150420 20 1 27100000 Amplification Thyroid cancer
9 151957 20 27100000 62435964 Amplification Thyroid cancer
10 153452 20 37100000 62435964 Gain Thyroid cancer
11 171643 3 170900000 182700000 Gain PIK3CA Thyroid cancer
12 171644 3 170900000 182700000 Gain PIK3CA Thyroid cancer
13 191662 5 1 45800000 Amplification Thyroid cancer
14 191664 5 1 45800000 Gain Thyroid cancer
15 200481 5 55800000 180857866 Gain Thyroid cancer
16 201091 5 65300000 159900000 Amplification Thyroid cancer
17 217036 7 1 158821424 Amplification Thyroid cancer
18 230743 8 1 19100000 Loss Thyroid cancer
19 236403 8 16100000 117700000 Amplification Thyroid cancer
20 236404 8 16100000 146274826 Gain Thyroid cancer
21 261707 X 24900000 59500000 Loss Thyroid cancer
22 303365 21 26028751 26066642 Deletion NRF2 Thyroid cancer

Expression for Thyroid Cancer

Search GEO for disease gene expression data for Thyroid Cancer.

Pathways for Thyroid Cancer

Pathways related to Thyroid Cancer according to KEGG:

38
# Name Kegg Source Accession
1 Thyroid cancer hsa05216
2 Transcriptional misregulation in cancer hsa05202

Pathways related to Thyroid Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 133)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.48 AKT1 BRAF HRAS KRAS NRAS PIK3CA
2
Show member pathways
13.45 AKT1 BRAF HRAS KRAS NRAS PIK3CA
3
Show member pathways
13.02 AKT1 BRAF HRAS KRAS NRAS PIK3CA
4
Show member pathways
13.02 AKT1 BRAF HRAS KRAS NRAS PIK3CA
5
Show member pathways
13.01 AKT1 BRAF HRAS KRAS NRAS PIK3CA
6
Show member pathways
13 AKT1 BRAF HRAS KRAS NRAS PIK3CA
7
Show member pathways
12.97 AKT1 BRAF HRAS KRAS NRAS PIK3CA
8
Show member pathways
12.94 AKT1 BRAF HRAS KRAS NRAS PIK3CA
9
Show member pathways
12.91 BRAF HRAS KRAS NRAS PIK3CA
10
Show member pathways
12.9 AKT1 HRAS KRAS NRAS PIK3CA
11 12.9 AKT1 BRAF HRAS KRAS NRAS PIK3CA
12
Show member pathways
12.89 AKT1 BRAF HRAS KRAS NRAS
13
Show member pathways
12.87 AKT1 BRAF HRAS KRAS PIK3CA
14
Show member pathways
12.87 AKT1 BRAF HRAS KRAS NRAS PIK3CA
15 12.86 AKT1 BRAF HRAS KRAS NRAS
16
Show member pathways
12.84 AKT1 BRAF HRAS KRAS NRAS
17
Show member pathways
12.84 AKT1 BRAF HRAS KRAS NRAS PIK3CA
18
Show member pathways
12.83 AKT1 HRAS KRAS NRAS PIK3CA
19
Show member pathways
12.81 AKT1 BRAF HRAS KRAS NRAS PIK3CA
20
Show member pathways
12.8 AKT1 BRAF HRAS KRAS NRAS PIK3CA
21
Show member pathways
12.78 AKT1 BRAF HRAS KRAS NRAS
22
Show member pathways
12.77 AKT1 HRAS KRAS NRAS PIK3CA
23
Show member pathways
12.77 AKT1 BRAF HRAS KRAS NRAS
24 12.74 BRAF HRAS KRAS NRAS PIK3CA
25
Show member pathways
12.7 AKT1 HRAS KRAS NRAS PIK3CA
26
Show member pathways
12.7 AKT1 HRAS KRAS NRAS PIK3CA
27
Show member pathways
12.67 AKT1 HRAS KRAS NRAS PIK3CA
28
Show member pathways
12.65 AKT1 BRAF HRAS KRAS NRAS PIK3CA
29
Show member pathways
12.63 BRAF HRAS KRAS NRAS PIK3CA
30
Show member pathways
12.63 AKT1 BRAF HRAS KRAS NRAS PIK3CA
31
Show member pathways
12.6 AKT1 HRAS KRAS NRAS PIK3CA
32 12.58 HRAS KRAS NRAS PIK3CA
33
Show member pathways
12.57 AKT1 HRAS KRAS NRAS PIK3CA
34
Show member pathways
12.56 AKT1 HRAS KRAS NRAS PIK3CA
35
Show member pathways
12.54 AKT1 BRAF HRAS KRAS NRAS
36
Show member pathways
12.53 AKT1 HRAS KRAS NRAS PIK3CA
37
Show member pathways
12.52 AKT1 HRAS KRAS NRAS PIK3CA
38
Show member pathways
12.52 AKT1 HRAS KRAS NRAS PIK3CA
39
Show member pathways
12.5 AKT1 HRAS KRAS NRAS PIK3CA SDC4
40
Show member pathways
12.49 BRAF HRAS KRAS NRAS PIK3CA
41 12.47 AKT1 HRAS KRAS NRAS PIK3CA
42
Show member pathways
12.44 AKT1 BRAF KRAS PIK3CA
43
Show member pathways
12.44 AKT1 BRAF HRAS KRAS NRAS
44
Show member pathways
12.42 AKT1 HRAS KRAS NRAS PIK3CA
45
Show member pathways
12.42 AKT1 HRAS KRAS NRAS PIK3CA
46
Show member pathways
12.41 AKT1 BRAF HRAS KRAS NRAS PIK3CA
47
Show member pathways
12.4 AKT1 HRAS PIK3CA SDC4
48
Show member pathways
12.4 AKT1 BRAF HRAS KRAS PIK3CA SDC4
49
Show member pathways
12.39 BRAF HRAS KRAS NRAS
50 12.39 HRAS KRAS NRAS PIK3CA

GO Terms for Thyroid Cancer

Biological processes related to Thyroid Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.61 AKT1 BRAF PIK3CA
2 Ras protein signal transduction GO:0007265 9.54 HRAS KRAS NRAS
3 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.5 HRAS KRAS NRAS
4 striated muscle cell differentiation GO:0051146 9.48 AKT1 KRAS
5 negative regulation of macroautophagy GO:0016242 9.46 AKT1 PIK3CA
6 negative regulation of neuron apoptotic process GO:0043524 9.46 BRAF HRAS KRAS PIK3CA
7 anoikis GO:0043276 9.4 AKT1 PIK3CA
8 MAPK cascade GO:0000165 9.35 BRAF HRAS KRAS NRAS RET
9 response to isolation stress GO:0035900 9.26 HRAS KRAS
10 positive regulation of gene expression GO:0010628 9.1 AKT1 BRAF CDKN2B-AS1 HRAS KRAS RET

Molecular functions related to Thyroid Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.02 BRAF HRAS KRAS NRAS RET

Sources for Thyroid Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....